Silencing TNFα activity by using Remicade or Enbrel blocks inflammation in whole muscle grafts: an in vivo bioassay to assess the efficacy of anti-cytokine drugs in mice

@article{Grounds2005SilencingTA,
  title={Silencing TNFα activity by using Remicade or Enbrel blocks inflammation in whole muscle grafts: an in vivo bioassay to assess the efficacy of anti-cytokine drugs in mice},
  author={Miranda D Grounds and Marilyn Davies and J. M. Torrisi and Thea Shavlakadze and Jason D. White and Stuart Hodgetts},
  journal={Cell and Tissue Research},
  year={2005},
  volume={320},
  pages={509-515}
}
Dramatic clinical success in the treatment of chronic inflammatory diseases has resulted from the use of anti-cytokine therapies including specific blocking antibodies, soluble receptors and traps to silence the actions of inflammatory cytokines such as tumour necrosis factor alpha (TNFα) and interleukin-1 (IL-1). Two agents used clinically to block the functional activity of TNFα protein are Remicade (an antibody) and Enbrel (a soluble TNF receptor). These tools are now being extended to many… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 33 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 27 references

Treatment of rheumatoid arthritis by TNF-blocking agents.

International archives of allergy and immunology • 2002
View 4 Excerpts
Highly Influenced

Crohn's disease: future anti-tumor necrosis factor therapies beyond infliximab.

Gastroenterology clinics of North America • 2004
View 2 Excerpts

Report on the 124th ENMC International Workshop. Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the use of corticosteroids

K Bushby, F Muntoni
Neuro Disord • 2004

Similar Papers

Loading similar papers…